Clinical Oncology evaluations can include various molecular tests and the results can influence patient care. One example of an Oncology Molecular Diagnostic is mutation analysis for genes known to be confer a high risk of cancer such as BRCA1/2. Healthy patients found to carry this mutation benefit from increased screening and surveillance due to their increased risk of several cancers.
Cell-free DNA (cfDNA) is a key analyte for liquid biopsy samples. Due to extremely low concentration and high degree of fragmentation, the extraction of cfDNA is technically challenging. Her...
Testing volumes need to increase by orders of magnitude in order to restore communities back to normality. This workshop focuses on solutions that equip laboratories to participate in expand...
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
In 2012, the Choosing Wisely initiative was commenced by the ABIM with numerous societies putting forward lists of overused tests or procedures. The Choosing Wisely movement has spread to nu...
The nuclear proliferation biomarker Ki-67 has multiple potential roles in breast and other cancers, both as a prognostic but also predictive marker. However, several studies have shown that...
Point-of-care testing (POCT) is destined to play a much greater role in chronic disease diagnosis and management. Advanced POCT systems are being developed to deliver less costly and more ac...
Clinical Laboratories have the opportunity to support value based health care by aligning with organizational strategies that focus on population health and creating meaningful insights usin...
The opioid crisis has put significant strain on the healthcare system and resources, including the clinical laboratory which has seen significant increases in requests for urine drug screeni...
Immunohistochemistry (IHC) is used to determine spatial relationships where we can identify the localization of target proteins in specific regions and cells of a tissue. IHC has been the go...
Patient laboratory test results are significantly over-represented in electronic medical records, but significantly under-utilized in research. An important application of laboratory data is...
Cases of traumatic brain injury (TBI) have been steadily rising over the past decade with most common causes of injury observed among participants in contact sports, combat military personne...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Identification of actionable mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology and the Oncomine Comprehensive Assay...
IIdentification of relevant mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology research and the Oncomine Comprehensi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
Date: October 15, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Renal transporters play an important role in potential clinical drug-drug interactions (DDIs) as highlighted in the FDA, EMA and PMDA...
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
Cell-free DNA (cfDNA) is a key analyte for liquid biopsy samples. Due to extremely low concentration and high degree of fragmentation, the extraction of cfDNA is technically challenging. Her...
Testing volumes need to increase by orders of magnitude in order to restore communities back to normality. This workshop focuses on solutions that equip laboratories to participate in expand...
Three-dimensional (3D) cell culture spheroids and aggregates are preferred over monolayer cell culture due to their architectural and functional similarity to solid tumors. To study expressi...
In 2012, the Choosing Wisely initiative was commenced by the ABIM with numerous societies putting forward lists of overused tests or procedures. The Choosing Wisely movement has spread to nu...
The nuclear proliferation biomarker Ki-67 has multiple potential roles in breast and other cancers, both as a prognostic but also predictive marker. However, several studies have shown that...
Point-of-care testing (POCT) is destined to play a much greater role in chronic disease diagnosis and management. Advanced POCT systems are being developed to deliver less costly and more ac...
Clinical Laboratories have the opportunity to support value based health care by aligning with organizational strategies that focus on population health and creating meaningful insights usin...
The opioid crisis has put significant strain on the healthcare system and resources, including the clinical laboratory which has seen significant increases in requests for urine drug screeni...
Immunohistochemistry (IHC) is used to determine spatial relationships where we can identify the localization of target proteins in specific regions and cells of a tissue. IHC has been the go...
Patient laboratory test results are significantly over-represented in electronic medical records, but significantly under-utilized in research. An important application of laboratory data is...
Cases of traumatic brain injury (TBI) have been steadily rising over the past decade with most common causes of injury observed among participants in contact sports, combat military personne...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Molecular testing of NCSLC biopsies is extremely important in the care and management of these patients. However, NCSLC biopsies are typically very small and require multiple types of analys...
Identification of actionable mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology and the Oncomine Comprehensive Assay...
IIdentification of relevant mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology research and the Oncomine Comprehensi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
Date: October 15, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Renal transporters play an important role in potential clinical drug-drug interactions (DDIs) as highlighted in the FDA, EMA and PMDA...
Soluble cytokine biomarkers are the master regulators of cell-to-cell communication-- the means by which one cell tells another what to do or where to go. Determining the biomarker signature...
While circulating cell-free DNA (ccfDNA) and to some extend CTCs from blood are routinely used as analyte in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) ha...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
